Todays Report: Today, JMP Securities Reiterates “Buy” Rating for Adamas Pharmaceuticals Inc. (ADMS)

Today, JMP Securities Reiterates “Buy” Rating for Adamas Pharmaceuticals Inc. (ADMS)

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)‘s stock had its “buy” rating reiterated by research analysts at JMP Securities in a research note issued to investors on Sunday.

ADMS has been the topic of several other reports. Mizuho reiterated a “buy” rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, September 23rd. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 11th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a research report on Wednesday, July 20th. Noble Financial reissued a “buy” rating and issued a $25.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, July 22nd. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $21.00 price objective on shares of Adamas Pharmaceuticals in a research report on Monday, July 25th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $30.33.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 0.25% on Friday, hitting $16.01. 88,576 shares of the stock were exchanged. The firm’s market capitalization is $351.93 million. Adamas Pharmaceuticals has a one year low of $12.02 and a one year high of $31.84. The company has a 50-day moving average price of $15.00 and a 200-day moving average price of $15.42.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.17. Adamas Pharmaceuticals had a negative net margin of 5,267.99% and a negative return on equity of 38.31%. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.26 million. During the same period in the previous year, the business earned ($0.81) EPS. The company’s revenue was down 81.8% compared to the same quarter last year. Equities research analysts expect that Adamas Pharmaceuticals will post ($2.91) earnings per share for the current year.

In related news, major shareholder Ix Lp Mdv bought 62,977 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Friday, September 16th. The stock was acquired at an average price of $16.48 per share, with a total value of $1,037,860.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William W. Ericson bought 43,719 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Friday, September 2nd. The shares were bought at an average cost of $14.75 per share, with a total value of $644,855.25. The disclosure for this purchase can be found here. 31.79% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Bamco Inc. NY bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $238,000. Sio Capital Management LLC increased its stake in shares of Adamas Pharmaceuticals by 17.0% in the third quarter. Sio Capital Management LLC now owns 66,110 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after buying an additional 9,610 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $2,833,000. Opus Point Partners Management LLC increased its stake in shares of Adamas Pharmaceuticals by 32.7% in the third quarter. Opus Point Partners Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock valued at $985,000 after buying an additional 14,802 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $198,000. 75.35% of the stock is owned by institutional investors and hedge funds.

About Adamas Pharmaceuticals

Related posts

Leave a Comment